Michael P. Bailey - Jan 19, 2023 Form 4 Insider Report for AVEO PHARMACEUTICALS, INC. (AVEO)

Role
President & CEO, Director
Signature
/s/ Danielle V. Holland, attorney in fact
Stock symbol
AVEO
Transactions as of
Jan 19, 2023
Transactions value $
-$4,997,505
Form type
4
Date filed
1/19/2023, 04:11 PM
Previous filing
Dec 22, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AVEO Common Stock Disposed to Issuer -$5M -333K -100% $15.00 0 Jan 19, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVEO Stock Option (Right to Buy) Disposed to Issuer -3.25K -100% 0 Jan 19, 2023 Common Stock 3.25K $77.20 Direct F2
transaction AVEO Stock Option (Right to Buy) Disposed to Issuer -12K -100% 0 Jan 19, 2023 Common Stock 12K $25.10 Direct F2
transaction AVEO Stock Option (Right to Buy) Disposed to Issuer -7.5K -100% 0 Jan 19, 2023 Common Stock 7.5K $17.70 Direct F2
transaction AVEO Stock Option (Right to Buy) Disposed to Issuer -90K -100% 0 Jan 19, 2023 Common Stock 90K $8.40 Direct F2
transaction AVEO Stock Option (Right to Buy) Disposed to Issuer -46K -100% 0 Jan 19, 2023 Common Stock 46K $10.80 Direct F2
transaction AVEO Stock Option (Right to Buy) Disposed to Issuer -75.4K -100% 0 Jan 19, 2023 Common Stock 75.4K $6.00 Direct F2
transaction AVEO Stock Option (Right to Buy) Disposed to Issuer -100K -100% 0 Jan 19, 2023 Common Stock 100K $30.80 Direct F2
transaction AVEO Stock Option (Right to Buy) Disposed to Issuer -16.8K -100% 0 Jan 19, 2023 Common Stock 16.8K $15.70 Direct F2
transaction AVEO Stock Option (Right to Buy) Disposed to Issuer -93.5K -100% 0 Jan 19, 2023 Common Stock 93.5K $6.20 Direct F2
transaction AVEO Stock Option (Right to Buy) Disposed to Issuer -35.3K -100% 0 Jan 19, 2023 Common Stock 35.3K $5.60 Direct F2
transaction AVEO Stock Option (Right to Buy) Disposed to Issuer -275K -100% 0 Jan 19, 2023 Common Stock 275K $9.12 Direct F2
transaction AVEO Stock Option (Right to Buy) Disposed to Issuer -625K -100% 0 Jan 19, 2023 Common Stock 625K $3.67 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Michael P. Bailey is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Pursuant to the Merger Agreement, at the Effective Time, each share of the Company's common stock automatically converted into the right to receive the Merger Consideration.
F2 This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes.

Remarks:

On January 19, 2022, pursuant to the Agreement and Plan of Merger (as it may be amended from time to time, referred to as the "Merger Agreement"), by and among LG Chem, Ltd. ("Parent"), Acacia acquisition Sub, Inc. ("Merger Sub") and AVEO Pharmaceuticals, Inc. (the "Company"), dated as of October 18, 2022, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent. Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of the Company's common stock automatically converted into the right to receive $15.00 per share in cash (the "Merger Consideration").